Posts belonging to Category Breaking News

Follow-Up to Letter to NIH Director Collins

Read about the encouraging results at: http://www.meaction.net/2016/09/09/members-of-congress-urge-nih-director-francis-collins-to-strengthen-biomedical-research-into-myalgic-encephalomyelitis-chronic-fatigue-syndrome/

First Approved ME/CFS Treatment in the World

Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic First Product Approved for ME/CFS Indication Anywhere in the World. Ampligen Approved in Argentina – First in the World 2016-08-23

2016 Membership Renewal

August is Membership Renewal Month Please support the work of NJME/CFSA.  See information at the link below. 2016-08 Membership Renewal Request

Announcing the Winners of ‪#‎MEAction‬’s Poetry Contest!

Link includes the 10 poems. http://bit.ly/1UICjb5 i.e. http://www.meaction.net/…/…/meactions-poetry-contest-winners

Medical Scholarship – See Scholarships tab at top of this page

Facebook Posts

Be sure to check out the NJME/CFSA Facebook page regularly for recent posts. https://www.facebook.com/New-Jersey-Chronic-Fatigue-Syndrome-Association-Inc-NJCFSA-141665745869451/

Trustee Kenneth Friedman, PHD participated in ME/CFS Awareness Day Panel

ImmuneDysfunction.org celebrated ME/CFS Awareness Day in the U.S. (May 12th, 2016) by holding a live television panel discussion concerning ME/CFS and Lyme disease on CCTV in Burlington, VT. I was honored to be included in the panel which consisted of physicians, an ME/CFS research and a VT State Senator; all of whom informed the audience […]

Governor Christie Declares May 2016 ME/CFS Awareness Month

High School Scholarship Application

2016 HS Scholarship Application

Letter to Agency for Healthcare Research and Quality (AHRQ)

Here is the second letter sent to the Agency for Healthcare Research and Quality (AHRQ) AHRQ Request Announcement Feb 3 2016 Letter to AHRQ